Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer

被引:2
|
作者
Zhou, Huijun [1 ]
Wu, Jie [2 ]
Shi, Lei [3 ]
Wang, Yu [1 ]
Liu, Bin [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Nucl Med, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
[2] Panzhihua Univ, Panzhihua Municipal Cent Hosp, Dept Nucl Med, Panzhihua, Sichuan, Peoples R China
[3] Chengdu Fifth Peoples Hosp, Dept Nucl Med, Chengdu, Sichuan, Peoples R China
基金
中国博士后科学基金;
关键词
PTC; papillary thyroid cancer; timing of surgery; radioactive iodine; I-131; therapy; clinical outcomes; ADULT PATIENTS;
D O I
10.1210/clinem/dgac502
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The optimal timing to performing thyroid surgery following a diagnosis of papillary thyroid cancer (PTC) has yet to be fully defined. Objective We aimed to examine if a delayed surgery may worsen the clinical outcome of PTC patients with intermediate- to high-risk of recurrence. Methods All consecutive PTC patients with intermediate- to high-risk of recurrence who underwent total thyroidectomy and radioactive iodine (RAI) ablation at 3 tertiary hospitals in southwest China were retrospectively included. Excellent response at 1-year follow-up after initial therapy was defined as no clinical, imaging, or biochemical evidence of PTC. Association of the timing of surgery and excellent response rates. Results The study included 871 patients. The median time interval between PTC diagnosis and surgery was 2 months (range, 1-87 months). Patients were divided according to the timing of surgery, < 6 months (group A, 624/871 [71.6%]), >= 6 to 11 months (group B, 123/871 [14.1%]), or >= 12 months (group C, 124/871 [14.2%]). One year after initial therapy, 64.7%, 71.5%, and 66.1% of patients in groups A, B, and C, respectively, achieved excellent response (P = 0.27). The lack of impact of surgery timing was observed across intermediate- to high-risk classifications and all T stage categories. These findings did not change when we separately analyzed the groups according to RAI dose (intermediate-dose group: <= 3.7 GBq [n = 654], and high-activity group: 5.5 GBq [n = 217]) further subdivided according to the timing of surgery. Conclusion Timing of surgery does not seem to affect short-term disease outcomes in intermediate- to high-risk PTC patients. Further research is necessary to assess the impact of delayed surgery on long-term prognosis.
引用
收藏
页码:3389 / 3397
页数:9
相关论文
共 50 条
  • [1] Association of Thyrotropin Suppression With Survival Outcomes in Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer
    Klubo-Gwiezdzinska, Joanna
    Auh, Sungyoung
    Gershengorn, Marvin
    Daley, Brianna
    Bikas, Athanasios
    Burman, Kenneth
    Wartofsky, Leonard
    Urken, Mark
    Dewey, Eliza
    Smallridge, Robert
    Chindris, Ana-Maria
    Kebebew, Electron
    JAMA NETWORK OPEN, 2019, 2 (02) : e187754
  • [2] Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus
    Lachant, Daniel
    Bach, Christina
    Wilson, Bennett
    Chengazi, Vaseem
    Goldman, Bruce
    Lachant, Neil
    Pietropaoli, Anthony
    Cameron, Scott
    James White, R.
    PULMONARY CIRCULATION, 2020, 10 (03)
  • [3] Clinical outcomes after delayed thyroid surgery in patients with papillary thyroid microcarcinoma
    Jeon, Min Ji
    kim, Won Gu
    Kwon, Hyemi
    Kim, Mijin
    Park, Suyeon
    Oh, Hye-Seon
    Han, Minkyu
    Sung, Tae-Yon
    Chung, Ki-Wook
    Hong, Suck Joon
    Kim, Tae Yong
    Shong, Young Kee
    Kim, Won Bae
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2017, 177 (01) : 25 - 31
  • [4] Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis
    Barata, Pedro C.
    Magi-Galluzzi, Cristina
    Gupta, Ruby
    Dreicer, Robert
    Klein, Eric A.
    Garcia, Jorge A.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (05) : 366 - 372
  • [5] Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer
    Abe, Koichiro
    Ishizaki, Umiko
    Ono, Toshihiro
    Horiuchi, Kiyomi
    Kanaya, Kazuko
    Sakai, Shuji
    Okamoto, Takahiro
    ANNALS OF NUCLEAR MEDICINE, 2020, 34 (02) : 144 - 151
  • [6] Reflective analysis on the current 131I adjuvant therapy indications in intermediate- and high-risk differentiated thyroid cancer
    Sun, Yuqing
    Zhao, Yihan
    Sun, Di
    Mu, Xingyu
    Li, Jiao
    Lu, Chenghui
    Lu, Lu
    Lin, Chunhao
    Lv, Jinfu
    Li, Ruochen
    Wang, Xufu
    Pan, Yijin
    Cheng, Wuying
    Lin, Yan-Song
    Fu, Wei
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [7] Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort
    Farrell, Rhonda
    Dixon, Suzanne C.
    Carter, Jonathan
    Webb, Penny M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (07) : 1379 - 1386
  • [8] Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer
    Zhang, Xin
    Liu, Jie-Rui
    Mu, Zhuan-Zhuan
    Cheng, Xin-Qi
    Lin, Yan-Song
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (06) : 1330 - 1337
  • [9] The impacts of minimally invasive surgery on intermediate- or high-risk cervical cancer patients received adjuvant radiotherapy
    Zhang, Qiying
    Liu, Zi
    Wang, Yali
    Zhang, Jing
    Li, Wen
    Wang, Tao
    Wang, Juan
    Shi, Fan
    Su, Jin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [10] Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study
    He, Tao
    Li, Ming
    Gao, Zheng-lian
    Li, Xiang-yu
    Zhong, Hai-rong
    Ding, Cui-shuang
    Cai, Hua-wei
    NUCLEAR MEDICINE COMMUNICATIONS, 2024, 45 (09) : 779 - 787